Category: 3. Business

  • Undeclared sulphur dioxide and incorrectly declared milk in Le Paysan 4 Pate Gift Pack

    Undeclared sulphur dioxide and incorrectly declared milk in Le Paysan 4 Pate Gift Pack


    Undeclared sulphur dioxide and incorrectly declared milk in specific batches of Le Paysan 4 Pate Gift Pack


    Friday, 19 December 2025









    Alert Summary
    Allergy Alert Notification: 2025.A47 Update 1
    Allergen(s): Sulphur dioxide and sulphites, milk
    Product Identification: Please see table below for product details.
    Batch Code Please see table below for batch codes and use-by dates.
    Country Of Origin: Ireland


    Message:
    Further to food allergen alert 2025.A47, the recall has been extended to cover specific batches of Le Paysan 4 Pate Gift Packs. The gift packs contain Le Paysan Smoked Mackerel Pate and Le Paysan Smoked Salmon Pate. 

    The below batches of Le Paysan 4 Pate Gift Packs contain sulphur dioxide which is not declared in the list of ingredients. Milk is also not emphasised in the ingredients list. This may make the batches unsafe for consumers who are allergic to or intolerant of sulphur dioxide and/or milk and therefore, these consumers should not eat the implicated batches. The affected batches are being recalled. 

     





















    Product name Batch code Use-by date
    Le Paysan 4 Pate Gift Pack 25273-04 21/01/2026
    25266-04 29/01/2026
    25245-04 01/02/2026
    25245-05 01/02/2026
    25281-01  08/02/2026
    25283-01 09/02/2026
    25259-06 15/02/2026
    25295-03  20/02/2026
    25295-04  20/02/2026
    25300-03 27/02/2026
    25315-05 17/03/2026
    25322-01 11/03/2026
    25332-01 17/03/2026
    25332-02 17/03/2026
    25337-02  27/03/2026
    25340-02  04/04/2026
    25344-03 08/04/2026















    Continue Reading

  • The Loan Closet of Howard County

    The Loan Closet of Howard County

    Receiving Equipment

    The Loan Closet of Howard County is a Durable Medical Equipment Re-Use program. Many residents of our county require the use of durable medical equipment (DME) such as wheelchairs, walkers, shower chairs, and other assistive devices, in order to maintain their safety and mobility either on a short term or long term basis. Often the cost of this equipment is a financial burden, not only to uninsured residents, but also to insured residents whose insurance will not approve the equipment needed or whose approval is delayed. We provide DME to Howard County residents with any injury, illness, or medical status, regardless of age, at no cost.

    1. Step 1: The Referring Provider (MD, PT, OT, DO, PA, or CRNP only) assesses the need for DME & obtains a Healthcare Referral Form. The Healthcare referral form is necessary to ensure that the client is safe & able to use the prescribed equipment.
    2. Step 2: The Referring Provider fills out the Provider Information section, checks off the equipment they are recommending for the client & signs the form. The Client Information section can be filled out by the Referring Provider or the Client/Caregiver.
    3. Step 3: Once all sections of the Healthcare Referral Form are completed, the form should be submitted (by either party) to our program via fax: 410-313-0369 or email: loancloset@howardcountymd.gov  
    4. Step 4: Once the Loan Closet receives the completed Healthcare Referral form, we will contact the client/caregiver via the phone number provided. If the equipment is in stock, a pick-up appointment will be scheduled. The appointment ensures that the Loan Closet Staff can verify that the requested equipment is in stock, cleaned & ready to distributed by the scheduled pick-up time. Note: If the pick-up appointment needs to be scheduled with a party other than the Client, please put their name & phone number in Section 4(Person Picking Up Equipment).
    • Equipment Flow Chart Graphic

    Continue Reading

  • Health Canada Opens Formal Consultations on Red Tape Reduction Initiatives to Improve Access to Drugs

    Health Canada Opens Formal Consultations on Red Tape Reduction Initiatives to Improve Access to Drugs

    December 19, 2025 | Ottawa, Ontario | Health Canada

    Today, the Honourable Marjorie Michel, Minister of Health, announces the launch of consultations for two regulatory initiatives, marking progress in Health Canada’s efforts to reduce red tape. These proposals, the Ministerial Reliance Order and regulations for Clinical Trial modernization are expected to reduce barriers to innovation, introduce new ways of conducting clinical trials and provide better access to drugs not available in Canada.

    The Ministerial Reliance Order will allow Health Canada to review certain parts of a drug submission more efficiently by leveraging decisions made by other trusted regulators without compromising quality, efficacy, and safety. These changes build on Health Canada’s long history of cooperation with its international counterparts and will support greater and faster access to drugs in Canada.

    Health Canada is also proposing a new regulatory framework for clinical trials for drugs that would build on the success of the existing clinical trials framework and further facilitate participant access, support innovation and enhance participant safety. This approach will provide Canadians with access to a wider range of products that could have significant health and economic benefits, including by providing quicker access to new therapies.

    Continue Reading

  • Silver climbs to record high, gold posts weekly gain on rate cut bets – Reuters

    1. Silver climbs to record high, gold posts weekly gain on rate cut bets  Reuters
    2. Silver Price Outlook – Silver Continues to Look Strong  FXEmpire
    3. Silver Price Forecast: XAG/USD bounces off 100-hour SMA; sticks to gains near $62.50  FXStreet
    4. From Weddings to Savings: Silver gains ground in Kashmir as prices soar  Greater Kashmir
    5. Silver Price Today at 9:34 (Dec 19, 2025): XAG/USD Near $66 as Softer US Inflation Keeps Fed Cut Bets Alive  ts2.tech

    Continue Reading

  • CUPE members sound the alarm on significant payroll issues at Iler Lodge

    CUPE members sound the alarm on significant payroll issues at Iler Lodge

    Workers at the Extendicare-run Iler Lodge are sounding the alarm after months of issues with the new payroll system has left some dreading the holidays. The roughly 140 members of CUPE 1370 have filed three grievances and have been trying to work with management to resolve issues caused by a new payroll system that the long-term care facility rolled out earlier this year.

    Every pay period brings up new issues, from unpaid top-ups for PSWs and nursing staff, to issues with the vacation and time off allotments.

    CUPE has been working with management to correct the issues with they pay system since May, but the issues have persisted in the Essex home. Similar issues also occurred in other Extendicare facilities in the province, but in Essex the issues persist. The members show up every day to provide continuity of care and service to the community, and the employer has been taking advantage of their compassion by failing to show the same respect and commitment in paying employees accurately and on time.

    “These are members who are already marginalized, already working multiple jobs to cover their bills,” said Suanne Hawkins, National Representative for local 1370. “Something must be done.”

    The union is preparing to escalate if the situation is not resolved soon.

    Members of CUPE 1370 want to share their experiences to shine a light on the issues they are facing in the hopes that management will take the initiative to fix the errors in the system and ensure that these pay issues stop.

    Continue Reading

  • FTC Approves Modifications to Horseracing Integrity and Safety Authority’s Enforcement Rule

    FTC Approves Modifications to Horseracing Integrity and Safety Authority’s Enforcement Rule

    The Federal Trade Commission issued an order approving a proposed modification from the Horseracing Integrity and Safety Authority to its Enforcement Rule. The modification includes new requirements for the Authority to seek Commission approval to issue a subpoena or commence a civil action under the Horseracing Integrity and Safety Act.

    The Act requires the Authority to submit proposed rules and any modifications to those rules to the FTC for approval. The Act requires that the FTC, after providing an opportunity for public comment, approve submitted rules if it finds that they are “consistent with” the Act and the FTC’s rules.

    Following a public comment period, the FTC voted 2-0 to approve the Enforcement Rule modification. The modification approved by the Commission and announced today will take effect on January 18, 2026.

    Continue Reading

  • Attorney General Hanaway Warns Missourians About Holiday Gift Card Scams as Shopping Season Intensifies

    JEFFERSON CITY, Mo. – Missouri Attorney General Catherine Hanaway is urging Missourians to stay vigilant this holiday season as scammers increasingly target consumers through deceptive and high-pressure gift card schemes. With millions of dollars lost nationwide each year to gift card fraud, Attorney General Hanaway warned that criminals often use fear, urgency, and impersonation tactics to trick victims into sending money that is nearly impossible to recover once redeemed.

    “As families across Missouri prepare for the holidays, criminals are preparing too, and they are counting on people being distracted or rushed,” said Attorney General Hanaway. “Our Office will not tolerate scammers who prey on hardworking Missourians, especially during a time of year that should be marked by generosity and joy. We are here to help, and we will continue doing everything we can to protect consumers and shut down fraudulent schemes.”

    Gift card scams typically begin with an unexpected call, text, email, or social-media message. Scammers pretend to be government officials, utilities, employers, or even loved ones. They then pressure victims to buy gift cards, often from Walmart, Target, CVS, Walgreens, Google Play, Apple, or Amazon, and demand the card number and PIN. Once the scammer has the code, the money is gone. These schemes rely heavily on urgency and fear, and no legitimate organization will ever demand payment by gift card.

    Attorney General Hanaway offered the following tips to help Missourians spot and avoid these scams:

    • Scammers create false emergencies. They will claim something terrible will happen unless you act immediately. Slow down. If someone demands payment by gift card, it’s a scam.
    • Scammers tell you exactly which gift card to buy and where to buy it. They may direct you to Walmart, Target, CVS, Walgreens, or ask for specific cards like Google Play, Apple, Amazon, or eBay. Some even stay on the phone while you shop. Hang up. It’s a scam.
    • Scammers will ask for the gift card number and PIN. Once you give those numbers or send a photo, the scammer can drain the funds instantly, even if the card never leaves your hand. Do not share those numbers. It’s a scam.

     

    If you have already purchased a gift card and given someone the numbers, you should:

    • Report the scam to the gift card company immediately.
    • Ask if reimbursement is possible. Some retailers have begun offering support to victims when fraud is caught quickly.

    Attorney General Hanaway encouraged anyone who believes they have been targeted or victimized by a scam to contact the Attorney General’s Consumer Protection Hotline at 800-392-8222 or file a complaint online at ago.mo.gov.

    Continue Reading

  • Settlement Reached in Multiple PUCO FirstEnergy Proceedings

    AKRON, Ohio, Dec. 19, 2025 — FirstEnergy Corp.’s Ohio electric companies – Ohio Edison, Toledo Edison and The Illuminating Company – have reached an agreement with parties to settle multiple Public Utilities Commission of Ohio (PUCO) matters and provide $275 million to FirstEnergy’s Ohio customers.

    The settlement resolves four PUCO proceedings – the Corporate Separation, Rider DMR and Rider DCR matters that were the subjects of the PUCO’s Nov. 19 orders and the pending Political and Charitable Spending review. The PUCO’s Nov. 19 orders directed the companies to pay $250 million, with $64 million going to the state general fund. If approved by the PUCO, the settlement will direct all $250 million to all customers and add $25 million exclusively for residential customers.

    Torrence Hinton, FirstEnergy President, Ohio: “We appreciate the dedication and collaboration shown by all parties and are grateful for the collective effort that led to an agreement that provides even more dollars to our Ohio customers. With these matters reaching resolution, we’re moving ahead with a clear focus on operating with transparency, delivering reliable service and investing in Ohio communities.”

    Key Settlement Details 

    Settlement provisions include:

    • $250 million in restitution and refunds, credited to customer bills in 2026
    • $25 million in additional restitution exclusively to residential customers, including $20 million for low-income bill payment assistance, weatherization and energy efficiency programs

    Parties to the settlement include The Office of the Ohio Consumers’ Counsel (OCC), Ohio Manufacturers’ Association Energy Group (OMAEG), Ohio Energy Group (OEG), Northeast Ohio Public Energy Council (NOPEC), Northwest Ohio Aggregation Coalition (NOAC), Ohio Partners for Affordable Energy (OPAE), Citizens Utility Board of Ohio (CUB Ohio), Interstate Gas Supply, LLC (IGS), Retail Energy Supply Association (RESA), NRG/Direct Energy Services, LLC and Direct Energy Business, LLC, Ohio Environmental Council (OEC), Ohio Cable Telecommunications Association (OCTA) and FirstEnergy’s Ohio utilities.

    Focused on the Future

    Between 2025 and 2029, FirstEnergy plans to invest $14 billion in Ohio’s transmission and distribution infrastructure, workforce and facilities – critical improvements that enhance reliability, support economic growth and prepare for future energy needs. The company looks forward to working constructively with the PUCO and other stakeholders to meet the needs of customers and communities across Ohio.

    FirstEnergy (NYSE: FE) is dedicated to integrity, safety, reliability and operational excellence. Its electric distribution companies form one of the nation’s largest investor-owned electric systems, serving more than six million customers in Ohio, Pennsylvania, New Jersey, West Virginia, Maryland and New York. The company’s transmission subsidiaries operate approximately 24,000 miles of transmission lines that connect the Midwest and Mid-Atlantic regions. Follow FirstEnergy on X @FirstEnergyCorp or online at firstenergycorp.com.

    Forward-Looking Statements: This Letter includes forward-looking statements based on information currently available to management and unless the context requires otherwise, references to “we,” “us,” “our” and “FirstEnergy” refers to FirstEnergy Corp. and its subsidiaries. Such statements are subject to certain risks and uncertainties and readers are cautioned not to place undue reliance on these forward-looking statements. These statements include declarations regarding management’s intents, beliefs and current expectations. These statements typically contain, but are not limited to, the terms “anticipate,” “potential,” “expect,” “forecast,” “target,” “will,” “intend,” “believe,” “project,” “estimate,” “plan” and similar words. Forward-looking statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements, which may include the following: the potential liabilities, increased costs and unanticipated developments resulting from government investigations and agreements, including those associated with compliance with or failure to comply with the Deferred Prosecution Agreement entered into July 21, 2021 and settlements with the U.S. Attorney’s Office for the Southern District of Ohio and the Securities and Exchange Commission (“SEC”); the risks and uncertainties associated with government investigations and audits regarding Ohio House Bill 6, as passed by Ohio’s 133rd General Assembly (“HB 6”) and related matters, including potential adverse impacts on federal or state regulatory matters, including, but not limited to, matters relating to rates; the risks and uncertainties associated with litigation, arbitration, mediation and similar proceedings, particularly regarding HB 6 related matters; changes in national and regional economic conditions, including recession, volatile interest rates, inflationary pressure, supply chain disruptions, higher fuel costs, workforce impacts, affecting us and/or our customers and those vendors with which we do business; variations in weather, such as mild seasonal weather variations and severe weather conditions (including events caused, or exacerbated, by climate change, such as wildfires, hurricanes, flooding, droughts, high wind events and extreme heat events) and other natural disasters, which may result in increased storm restoration expenses or material liability and negatively affect future operating results; the potential liabilities and increased costs arising from regulatory actions or outcomes in response to severe weather conditions and other natural disasters; legislative and regulatory developments, and executive orders, including, but not limited to, matters related to rates, energy regulatory policies, compliance and enforcement activity, cyber security, climate change, and equity and inclusion; the ability to access the public securities and other capital and credit markets in accordance with our financial plans, the cost of such capital and overall condition of the capital and credit markets affecting us, including the increasing number of financial institutions evaluating the impact of climate change on their investment decisions, and the loss of FirstEnergy Corp.’s status as a well-known seasoned issuer; the risks associated with physical attacks, such as acts of war, terrorism, sabotage or other acts of violence, and cyber-attacks and other disruptions to our, or our vendors’, information technology system, which may compromise our operations, and data security breaches of sensitive data, intellectual property and proprietary or personally identifiable information; the ability to accomplish or realize anticipated benefits through establishing a culture of continuous improvement and our other strategic and financial goals, including, but not limited to, executing Energize365, our transmission and distribution investment plan, executing on our rate filing strategy, controlling costs, improving credit metrics, maintaining investment grade ratings, strengthening our balance sheet and growing earnings; changing market conditions affecting the measurement of certain liabilities and the value of assets held in our pension trusts may negatively impact our forecasted growth rate, results of operations and may also cause it to make contributions to its pension sooner or in amounts that are larger than currently anticipated; changes in assumptions regarding factors such as economic conditions within our territories, the reliability of our transmission and distribution system, our generation resource planning in West Virginia, or the availability of capital or other resources supporting identified transmission and distribution investment opportunities; human capital management challenges, including among other things, attracting and retaining appropriately trained and qualified employees and labor disruptions by our unionized workforce; mitigating exposure for remedial activities associated with retired and formerly owned electric generation assets, including those sites impacted by the legacy coal combustion residual rules that were finalized during 2024, and the Environmental Protection Agency’s reconsideration of such rule; changes to environmental laws and regulations, including, but not limited to, federal and state rules related to climate change, and potential changes to such laws and regulations as a result of the U.S. presidential administration; changes in customers’ demand for power, including, but not limited to, economic conditions, the impact of climate change, and emerging technology including artificial intelligence, particularly with respect to electrification, energy storage and distributed sources of generation; future actions taken by credit rating agencies that could negatively affect either our access to or terms of financing or our financial condition and liquidity; the potential of noncompliance with debt covenants in our credit facilities; the ability to comply with applicable reliability standards and energy efficiency and peak demand reduction mandates; changes to significant accounting policies; any changes in tax laws or regulations, including, but not limited to, the Inflation Reduction Act of 2022, the One Big Beautiful Bill Act of 2025, as signed into law on July 4, 2025, or adverse tax audit results or rulings and potential changes to such laws and regulations; the ability to meet our publicly-disclosed goals relating to climate-related matters, opportunities, improvements, and efficiencies, including FirstEnergy’s Greenhouse gas reduction goals’ and the risks and other factors discussed from time to time in FirstEnergy Corp.’s SEC filings. Dividends declared from time to time on FirstEnergy Corp.’s common stock during any period may in the aggregate vary from prior periods due to circumstances considered by the FirstEnergy Corp. Board at the time of the actual declarations. A security rating is not a recommendation to buy or hold securities and is subject to revision or withdrawal at any time by the assigning rating agency. Each rating should be evaluated independently of any other rating. These forward-looking statements are also qualified by, and should be read together with, the risk factors included in FirstEnergy Corp.’s Form 10-K, Form 10-Q and in other filings with the SEC. The foregoing review of factors also should not be construed as exhaustive. New factors emerge from time to time, and it is not possible for management to predict all such factors, nor assess the impact of any such factor on FirstEnergy Corp.’s business or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statements. FirstEnergy Corp. expressly disclaims any obligation to update or revise, except as required by law, any forward-looking statements contained herein or in the information incorporated by reference as a result of new information, future events or otherwise.

     

    CONTACT: News Media Contact: Jennifer Young, 330-761-4362; Investor Contact: Karen Sagot, 330-761-4286


    Continue Reading

  • President Donald J. Trump Announces Largest Developments to Date in Bringing Most-Favored-Nation Pricing to American Patients – The White House

    President Donald J. Trump Announces Largest Developments to Date in Bringing Most-Favored-Nation Pricing to American Patients – The White House

    LOWERING DRUG PRICES FOR AMERICAN PATIENTS: Today, President Donald J. Trump announced nine new agreements with major pharmaceutical companies to lower prescription drug prices for Americans in line with the lowest prices paid by other developed nations (known as the most-favored-nation, or MFN, price).

    • The nine manufacturers include Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi.
    • The agreements reduce prices on drugs that treat numerous costly and chronic conditions, including type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), hepatitis B and C, human immunodeficiency virus (HIV), and certain cancers, among others.
    • The agreements will provide every State Medicaid program in the country access to MFN drug prices on products made by the nine companies, resulting in billions of dollars in savings and continuing President Trump’s historic efforts to strengthen the program for the most vulnerable.
    • The agreements ensure foreign nations can no longer use price controls to free ride on American innovation by guaranteeing MFN prices on all new innovative medicines the nine companies bring to market.
    • The agreements require the nine companies to repatriate increased foreign revenue on existing products that they realize as a result of the President’s strong America First U.S. trade policies for the benefit of American patients.
    • The agreements require the nine companies to offer medicines at a deep discount off the list price when selling directly to American patients through TrumpRx.

    DELIVERING LOWER COSTS: Patients will be able to see massive price reductions on numerous products when purchasing directly through TrumpRx as a result of today’s actions. Select examples include:

    • Amgen will reduce the price of its cholesterol-lowering drug Repatha from $573 to $239 for patients purchasing directly through TrumpRx.
    • Bristol Myers Squibb will reduce the price of its HIV medication, Reyataz, from $1,449 to $217 for patients purchasing directly through TrumpRx.
    • Boehringer Ingelheim will reduce the price of its type two diabetes medication, Jentadeuto, from $525 to $55 for patients purchasing directly through TrumpRx.
    • Genentech will reduce the price of its flu medication, Xofluza, from $168 to $50 for patients purchasing directly through TrumpRx.
    • Gilead Sciences will reduce the price of its Hepatitis C medication, Epclusa, from $24,920 to $2,425 for patients purchasing directly through TrumpRx.
    • GSK will reduce the prices of its inhaler portfolio. Prices for the popular asthma inhaler Advair Diskus 500/50 will fall from $265 to $89 for patients purchasing directly through TrumpRx.
    • Merck will reduce the price of its diabetes medication, Januvia, from $330 to $100 for patients purchasing directly through TrumpRx.
    • Novartis will reduce the price of its Multiple Sclerosis medication, Mayzent, from $9,987 to $1,137 for patients purchasing directly through TrumpRx.
    • Sanofi will reduce the price of its prescription blood thinner, Plavix, from $756 to $16 for patients purchasing directly through TrumpRx and Sanofi will list its insulin products at TrumpRx at $35 per month’s supply.

    BOLSTERING NATIONAL HEALTH SECURITY BY INVESTING IN AMERICA: The pharmaceutical manufacturers involved in today’s announcement are committing to invest at least $150  billion collectively in U.S. manufacturing in the near term. Additionally, as part of the agreements, several companies are donating active pharmaceutical ingredients for key products to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to reduce reliance on foreign nations and ensure the United States has an adequate supply of such products in the event of an emergency.

    • GSK will contribute 98.8kg of albuterol, the active ingredient in a common rescue inhaler for people with asthma.
    • Bristol Myers Squibb will contribute tablets representing 6.5 tons of apixaban, the active ingredient in the drug Eliquis, a blood thinner taken by millions of American patients.
    • Merck will contribute 3.5 tons of ertapenem, an antibacterial medication used to treat complex infections.

    DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST: President Trump is delivering on promises to ensure American patients no longer pay high prices to subsidize low prices in the rest of the world, something the political establishment did not believe was possible.

    • On May 12, 2025, President Trump signed an Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” directing the Administration to take numerous actions to bring American drug prices in line with those paid by similar nations.
    • On July 31, 2025, President Trump sent letters to leading pharmaceutical manufacturers outlining the steps they must take to bring down the prices of prescription drugs in the United States to match the lowest price offered in other developed nations.
    • Since September 30, 2025, President Trump has announced 14 deals with major pharmaceutical manufacturers to bring prices in line with those paid in other developed nations, which will provide substantial price relief on numerous products taken by millions of Americans.
    • On December 1, 2025, the Office of the United States Trade Representative, the Department of Commerce, and the Department of Health and Human Services announced an agreement with the United Kingdom (U.K.) that will increase the net price of new prescription drugs by 25% in the U.K., helping ensure they pay their fair share for innovative medicines.

    Continue Reading

  • Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans

    Enlicitide has potential to be first approved oral PCSK9 inhibitor designed to help meet critical unmet needs for patients and will be offered at an affordable price to eligible Americans through a direct-to-patient program

    Merck has committed more than $70 billion in U.S. investments to boost domestic production and innovation


    Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a historic agreement with the Trump administration to ensure its prescription medicines are both accessible and affordable for Americans. This agreement enables Merck to continue its long-standing commitment to develop and deliver life-changing medicines and vaccines, and ensure Americans have access to those innovations at lower costs.

    “As an American company, Merck is proud to work with the Trump administration to further secure our country’s position as a world leader in biopharmaceutical innovation. Today’s agreement marks a pivotal step in ensuring Americans can access medicines they need at lower costs,” said Robert M. Davis, chairman and chief executive officer, Merck. “For too long, global pricing imbalances have shifted the financial burden of groundbreaking research and development onto the U.S. health care system and ultimately, American patients. Merck remains committed to expanding access and improving affordability across the system.”

    Merck is working with the administration to reduce disparities in drug prices between the U.S. and other nations so American patients no longer shoulder a disproportionate share of the cost of innovation. Merck is voluntarily addressing all four components of the president’s July letter and taking steps that will help ensure Americans can benefit from lower prices and broader access to prescription medicines.

    Information on Merck’s agreement with the Trump administration

    Merck plans to provide key products through a direct-to-patient program at affordable prices for eligible patients in the U.S. This currently includes JANUVIA, JANUMET and JANUMET XR, and will be expanded in the future to include enlicitide decanoate following FDA approval.

    JANUVIA, JANUMET and JANUMET XR will be available to eligible American patients at a cash price — approximately 70% off of the current list price — through a direct-to-patient program.

    Enlicitide, a novel candidate to lower LDL cholesterol, was designed to deliver PCSK9 antibody-like efficacy in an easy-to-use daily pill. Although existing injectable PCSK9 inhibitors are effective, they remain widely underused. The cardiovascular (CV) epidemic is the leading cause of deaths in America with heart attacks and stroke contributing to most of the CV deaths — one person dies every 36 seconds from cardiovascular disease. If approved, we intend to make enlicitide broadly available as an affordable option for American patients to help address the CV epidemic.

    Additionally, the company reached an understanding with the U.S. Department of Commerce to delay Section 232 tariffs for three years, enabling the company to make investments in the United States to reshore manufacturing for American patients.

    Merck investments in American innovation

    Merck has accelerated its commitment to U.S. innovation and manufacturing, building on its 15 manufacturing and R&D facilities and a strong workforce in the U.S. of more than 30,000. The company has invested over $12 billion in U.S. manufacturing since 2017 and $81 billion in U.S.-based R&D since 2018, supporting tens of thousands of American jobs. Over the next several years, Merck will invest more than $70 billion in capital and R&D spending, including at least $12 billion in capital expenditures, to drive long-term growth and strengthen the U.S. position as a global leader in biopharmaceutical innovation. This includes Merck’s recent announcements of manufacturing facilities in Virginia, Kansas and Delaware, which alone will create 1,200 full-time jobs and support 15,000 construction jobs.

    About Merck

    At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world — and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

    Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

    This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

    Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

    The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

    Appendix

    Generic product names are provided below.

    • JANUMET (sitagliptin and metformin HCl)
    • JANUMET XR (sitagliptin and metformin HCI extended-release)
    • JANUVIA (sitagliptin)


    Source: Merck & Co., Inc., Rahway, NJ, USA


    Continue Reading